Introduction {#s0001}
============

Enterococci are medically important opportunistic pathogen which are more common in hospital-acquired infections. Linezolid[@cit0001] is the first clinically used oxazolidinone antibiotic for the treatment of multidrug-resistant (MDR) gram-positive infections, especially in vancomycin-resistant enterococci (VRE) and methicillin-resistant *Staphylococcus aureus* (MRSA).[@cit0002] However, linezolid-resistant enterococci have been increasingly detected both in human and animals[@cit0003] in recent years, which urgently demands to deepen our knowledge on its resistance mechanisms.

The resistance of linezolid in enterococci can be caused by point substitutions in 23S rRNA V domain, the main reason for linezolid resistance.[@cit0004] The 23S rRNA methyltransferase coding genes *cfr*,[@cit0004] *cfr*(B), *cfr*(C)[@cit0005] and *cfr*(D)[@cit0006] and also amino acid substitutions in ribosomal proteins L3, L4,[@cit0004] L22,[@cit0007] and ABC-F family members including OptrA[@cit0008] and PoxtA.[@cit0009] How ABC-F proteins mediate antibiotic resistance has been in a long-standing dispute with both efflux and ribosome protection hypothesis competing mutually. Current studies seem inclined to the latter.[@cit0010],[@cit0011] The *optrA*, found in 2015, was reported for its ATP hydrolysis activity to be associated with linezolid resistance.[@cit0012] Also, previous study reported that there were different amino acid substitutions in *optrA*.[@cit0013] In this study, we investigated the molecular characterization of *optrA*-positive enterococci and explored the function of varied types of *optrA* on the linezolid susceptibility.

Materials and Methods {#s0002}
=====================

Bacterial Strains {#s0002-s2001}
-----------------

We examined 573 strains collected in 2017 at Huashan hospital, a tertiary hospital from Shanghai in China ([Table 1](#t0001){ref-type="table"}). All were enterococci identified by bioMerieux Vitek-2 Compact and were stored in 30% glycerol broth under −80°C. The culture medium used in this study were BHIA (Brain-Heart Infusion Agar), BHIB (BrainHeart Infusion Broth), MHA (Mullex-Hinton Agar) and MHB (Mullex-Hinton Broth) (Thermo Fisher Oxoid, England).Table 1The Distribution of Different Species of Enterococcus Isolates from Huashan Hospital in 2017Bacterial StrainsNumber (n)Percentage*E. faecalis*29651.66%*E. faecium*26446.07%*E. avium*91.57%*E. casseliflavus*20.35%*E. gallinarum*20.35%Total573100.00%

Screening of *optrA* and Other Linezolid Resistance Related Genes in Enterococci {#s0002-s2002}
--------------------------------------------------------------------------------

The length of *optrA* is 1968 bp.[@cit0008] We screened 573 enterococci mentioned above by using PCR. All DNA samples were amplified using primers *optrA*-F1 (5ʹ-CAGGTGGTCAGCGAACTAAGA-3ʹ) and *optrA*-R1 (5ʹ-AGCCAAGAGCAGTTCTGACC-3ʹ), of which the product size was 792 bp. The thermal conditions were 1 cycle of 94°C for 5 min followed by 30 cycles of 94°C for 30 s, 56°C for 30 s, and 72°C for 30 s and 72°C for 5 min to stop the extension step. Then, amplifications were carried out in the *optrA*-positive strains for getting the whole sequence of *optrA* and detecting the existence of *cfr*,[@cit0014] *cfr*(B), *cfr*(C), *poxtA* and mutations in *rplC, rplD*,[@cit0015] *rplV*, and 23S rRNA V domain[@cit0016] which were associated with linezolid resistance. Primers of these amplifications were shown in [[Supplementary 1](https://www.dovepress.com/get_supplementary_file.php?f=251490.pdf)]{.ul}.

Antimicrobial Susceptibility Testing {#s0002-s2003}
------------------------------------

The MIC for all *optrA*-positive isolates were determined by broth microdilution and agar dilution tests following the recommendations given in the Clinical and Laboratory Standards Institute (CLSI) documents M100-ED28.[@cit0017] *Enterococcus faecalis* ATCC29212 served as the quality control strain. These antimicrobial susceptibility tests involved 18 antibiotics (Shanghai Food and Drug Administration, Shanghai, China) which were listed in [[Supplementary 4](https://www.dovepress.com/get_supplementary_file.php?f=251490.pdf)]{.ul}. All tests were performed by using broth microdilution except for fosfomycin which was practiced with agar dilution. In CLSI, the approved MIC testing of fosfomycin is agar dilution, and the agar media should be supplemented with 25 μg/mL of glucose-6-phosphate.

Molecular Typing of *optrA*-Positive Enterococci {#s0002-s2004}
------------------------------------------------

The phylogenetic distance among isolates harboring *optrA* was analyzed by PFGE. The sequence typing (ST) of all *optrA*-positive enterococci were identified through MLST. The MLST analysis was on the basis of amplifying the seven housekeeping genes *gdh, gyd, psts, gki, aroE, xpt, yqil* in *E. faecalis* and the other seven genes *atpa, ddl, gdh, purk, gyd, psts, adk* in *Enterococcus faecium*. According to the sequences provided in PubMLST ([<https://pubmlst.org/data/>]{.ul}), primers for MLST were designed. All STs were determined by using the *Enterococcus* MLST database ([<https://pubmlst.org/efaecalis/and><https://pubmlst.org/efaecium/>]{.ul}).

Determination on the Function of Various Types of *optrA* {#s0002-s2005}
---------------------------------------------------------

From the study published in 2015,[@cit0008] the *optrA* found in plasmid pE394 (GenBank accession no. KP399637.1) was defined as the wildtype. A plasmid called *E. faecalis* JH2-2_pAM401Ω*optrA* was constructed to confirm that the *optrA* could result in the resistance of linezolid in enterococci. Therefore, in our research, in order to investigate the effects of the amino acid substitutions of *optrA* on linezolid resistance, we followed the steps in the aforementioned article for the construction of the plasmid OG1RF_pABG5.0Ω*optrA* (wildtype and mutations). pABG5.0[@cit0018] served as the shuttle vector which could exist both in *Escherichia coli* and *E. faecalis*.

In-Fusion HD Cloning Kits (Takara) were used in the experiment. After the successful construction, the plasmid was transferred into OG1RF,[@cit0019] a linezolid susceptible *E. faecalis* (MIC=2μg/mL), and then the *optrA*-positive clones were selected for further antimicrobial susceptibility test.

Results {#s0003}
=======

The Distribution of *optrA* and Its Molecular Types {#s0003-s2001}
---------------------------------------------------

In all 573 strains isolated from Huashan hospital in 2017, we detected 20 *optrA*-positive isolates, numbered as 8, 37, 91, 154, 155, 185, 216, 223, 280, 297, 366, 397, 402, 404, 413, 421, 422, 446, 550, and 551, which accounted for 3.48% of the total strains. In [Table 2](#t0002){ref-type="table"}, we could see that there were 14 *optrA* variants with 1 to 6 alterations at different positions. I104R, T112K, Y176D, and E256K were the most common amino acid substitutions; 18 of 20 strains were separated into 14 various STs, and the remaining two strains could not be identified in known STs.Table 2Twenty *optrA*-Positive Strains Were Numbered and Their MLST Types Were Listed as Shown Below. We Found the Existence of Various *optrA* Mutations Among Those 20 Which Presented Diverse MICs of Linezolid. According to CLSI, The Criteria of Judging Susceptibility Included Susceptible (MIC≤2μg/mL), Intermediate (MIC=4μg/mL), Resistant (MIC≥8μg/mL)IsolatesSpecies*optrA* Variant*optrA*STMIC (μg/mL)8efaKDT112K, Y176D330837efaRDKI104R, Y176D, E256K689491efaoptrAE394No mutations4762154efmDG40D3621155efaoptrAE394No mutations1344185efaRDKCI104R, Y176D, E256K, S399C3764216efaKDT112K, Y176D4602223efaDMY176D, I622M161280efaKVT112K, F642V161297efaoptrAE394No mutations44366efaDPY176D, T481P694397efaoptrAE394No mutations4762402efmDDY176D, G393D/2404efaKHRDIPT157K, Y158H, K160R, Y176D, V249I, T481P692413efmNDMD247N, G393D, I622M3232421efmDNDMY176D, D247N, G393D, I622M557≤0.5422efmKT112K782446efaRKI104R, E256K/4550efaRDKI104R, Y176D, E256K162551efaNI24N5858[^1]

The detection and amino acid substitutions of other linezolid-resistant-related genes were presented in [[Supplementary 2](https://www.dovepress.com/get_supplementary_file.php?f=251490.pdf)]{.ul}. All genes amplified above were compared with the sequences from *E. faecalis* and *E. faecium* attainable in NCBI. ([<https://www.ncbi.nlm.nih.gov/nuccore/NC_01-7316.1>]{.ul} and [<https://www.ncbi.nlm.nih.gov/genome/?term=Enterococcus+faecium+DO>]{.ul}). None amino acid substitution of 23S rRNA V domain was detected in *E*. faecalis. None of these 20 strains contained *cfr, cfr*(B), *cfr*(C) genes while 397 harbored *cfr*(D) gene. Nineteen strains had F101L mutations of L4, while no mutation of L22 was found, and G4K/D/R were the main mutation sites of L3. Only one strain possessed both *optrA* and *poxtA*.

For further study on whether there was the dissemination of *optrA* in Huashan hospital, we performed PFGE and MLST. Similarity among 20 strain patterns was figured out by computerized band analysis with Bionumerics software version 3.3. This part of results could be seen in [[Supplementary 3](https://www.dovepress.com/get_supplementary_file.php?f=251490.pdf)]{.ul}. No obvious homology was found in these 20 strains harboring *optrA*.

Antimicrobial Susceptibility Testing {#s0003-s2002}
------------------------------------

The results of the antimicrobial susceptibility testing were shown in [[Supplementary 4](https://www.dovepress.com/get_supplementary_file.php?f=251490.pdf)]{.ul}. All strains were resistant to tetracycline, kanamycin, erythromycin, and ciprofloxacin while they were susceptible to vancomycin and teicoplanin. The distribution of resistance in the remaining 8 antibiotics were followed by ampicillin (5/20, 25%), penicillin (5/20, 25%), linezolid (2/20, 10%), rifampicin (5/20, 20%), chloramphenicol (15/20, 75%), and fosfomycin (3/20, 15%). Only one strain was found with tigecycline MIC as 4 μg/mL. The imipenem MIC of 4 strains were equal to or over 8 μg/mL. More detailed tests on linezolid were further put into practice. Only two strains were found as linezolid resistant, obtained by broth microdilution separately.

Function of Two Types of *optrA* Variants in Linezolid Resistance {#s0003-s2003}
-----------------------------------------------------------------

Isolates 8 (*optrA*-KD) and 37 (*optrA*-RDK) were found containing the most common alterations of *optrA* among these 20 strains. Based on this result, they were chosen for the transformation. The successful transformants (designated OG1RF_pABG5.0Ω*optrA*-KD and OG1RF_pABG5.0Ω*optrA*-RDK) exhibited 2 to 4 folds increase in the MIC of linezolid compared with the recipient strain OG1RF ([Table 3](#t0003){ref-type="table"}).Table 3MICs for Clinical *E*. *faecalis* with *optrA* Variants, Their Transformants and Recipient StrainsBacterial IsolatesLinezolidMIC/μg/mLClinical *E*. *faecalis* HS0914 (wildtype)8 8 (KD)8 37 (RDK)4Recipient strain OG1RF2 Transformants OG1RF_pABG5.02 Transformants OG1RF_pABG5.0Ω*optrA* (wildtype)8 Transformants OG1RF_pABG5.0Ω*optrA* (KD)4 Transformants OG1RF_pABG5.0Ω*optrA* (RDK)4[^2]

Discussion {#s0004}
==========

In 2017, *E. faecalis* and *E. faecium* were two main types of bacterial pathogens isolated from Huashan hospital. The detection rate of *optrA* in 573 strains was not high. ST-16 was the type that commonly existed among 14 STs (3/20) as mentioned in [Table 2](#t0002){ref-type="table"} which coincided with the common type of enterococci harboring *optrA* in other districts.[@cit0020],[@cit0021] These comparisons indicated that *optrA* was carried by low-homology enterococci isolates.

The results of the antimicrobial susceptibility tests have revealed that multidrug-resistant enterococci were not the minority. Resistance levels of linezolid in enterococci containing *optrA* were unevenly distributed.

Through the method of broth microdilution, only two strains were detected with low linezolid resistant level (MIC=8 μg/mL). This conceded that *optrA* was not only present in linezolid-resistant enterococci. At the same time, 20 strains harboring *optrA* had different numbers of amino acid substitutions. In the preliminary experiments, the successful construction of *optrA* over-expressing strains had shown that KD (T112K, Y176D) (BankIt2317497 KD MT122998) and RDK (I104R, Y176D, E256K) (BankIt2317550 RDK MT122999) *optrA* variants were able to raise linezolid MIC but could not reach the MIC as shown in the wildtype *optrA* in pE349. Potential mechanisms of mutations that affected the level of resistance of the bacteria to linezolid deserve further study. However, not all types of variants were used to construct the plasmid for over-expressing the *optrA*. Interestingly, 91 and 397 with no mutation of *optrA* were susceptible to linezolid (MIC=2 μg/mL). Whether *optrA* gene expressed and translated or there were some other mechanisms antagonizing the ribosome protection mechanism which led to the loss of drug resistance phenotype will be another avenue of research.

Screening of other linezolid-resistant genes showed that the *cfr, cfr*(B), and *cfr*(C) detection rates were zero, which were consistent to the results of MIC. Only one *E*. *faecalis* was detected to carry *cfr*(D).In this year, a study from europe characterized the novel *cfr*(D) gene identified in an *E. faecium* clinical isolate.[@cit0006] According to the results mentioned above, it might probably that the *cfr*(D) gene tended to transfer between two kinds of *Enterococcus*. Whether it played a role of conferring linezolid resistance in *Enterococcus* still needs to be explored.

F101L mutation of L3 protein was common among 19 strains. Whether it participated in the process of linezolid resistance remains to be confirmed. For lack of the mature techniques of gene knockout in *Enterococcus*, it is not easy to verify the concrete functions of these substitutions.

The newly discovered PoxtA, which also belongs to ABC-F proteins, shares 32% homology identity with OptrA. Of the 20 strains, only 402 had OptrA (Y176D, G393D) and PoxtA (no alterations). Surprisingly these two displayed no synergistic effects because its MIC showed that it was a susceptible one. Whether they existed in one plasmid, like pE035 obtained from swine carrying both *optrA* and *poxtA*,[@cit0022] or neither was expressed or had other negative interactions is vague at the moment. Moreover, since 421 was extremely susceptible to linezolid (MIC\<0.5 μg/mL), whether its regulatory region was interfered still needs to be checked.

In conclusion, although the detection rate of *optrA* in *Enterococcus* spp. isolates was not high, and there was no obvious evidence of its dissemination in hospital, its role in linezolid resistance still needs to be noted. *OptrA* mutations affected the linezolid resistance at varying degrees. Detailed mechanisms such as how *optrA* variants interact with linezolid are of more need to be clarified.
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[^1]: **Notes:** K: Lys, D: Asp, R: Arg, C: Cys; M: Met, T: Thr; V: Val, E: Glu, H: His; I: Ile, P: Pro; N: Asn.

[^2]: **Notes:** HS0914: *optrA* with no mutation; KD: T112K, Y176D type; RDK: I104R, Y176D, E256K type.
